Irritable Bowel Syndrome Clinical Trial
Official title:
Efficacy of Low-FODMAPs Dietary Therapy Versus Traditional Dietary Advice for Diarrhea-predominant Irritable Bowel Syndrome in China - A Prospective Randomized Controlled Trial
The primary aim of our study is to carry out a randomized trial to evaluate the efficacy of low-FODMAPs dietary therapy compared to conventional therapy for IBS patients recruited from tertiary hospitals in China. Secondary aims of this research include an analysis of clinical, physiological and microbiological factors that may predict IBS patient response to this dietary intervention.
Visit 1:Enrollment & Screening & Run-in period Patients who meet the inclusion criteria will
be asked to complete IBS Baseline Assessment Questionnaires according to Rome III.Subjects
that meet the criteria will receive verbal and written information about the study and
provide written informed consent. After meeting with the dietitian and physician who will
provide instructions, they will be asked to complete Combined Nutrient and Lactulose Breath
Test.[16] Additionally, a baseline food and symptom diary will be completed in a (minimum) 14
day run-in period after breath test (the first 48hr after the breath test will not be
included in this analysis). This diary record prior to the intervention will document
baseline symptom severity and capture the habitual diet of IBS patients.
Visit 2: Randomization & Intervention. After the run-in period, patients will come back to
the clinic to receive dietary instruction ahead of starting the intervention. At the same
visit subjects will provide fresh stool for fermentation analysis (including short chain
fatty acids and pressure detection) and blood for cytokines analysis. Subjects will then be
randomly assigned to either low FODMAP diet (LFD) group or traditional dietary advice for IBS
(TDA) group by computer-generated random number table. Participants will receive food
instructions by a dietitian, according to their assignment. Throughout the study, only the
dietitian will be aware of the assignment of the intervention given. Both diet therapy will
last for 3 weeks, and all the subjects are instructed to complete daily food and symptom
diary through a provided booklet. IBS Symptoms Severity Scores (IBS-SSS) is evaluated every
week and the dietitian who is not aware of the allocation will make a telephone follow-up to
assess patient adherence.
Visit 3: End of treatment & Follow-up. After 3 weeks of intervention, the participants will
attend a follow-up appointment and complete the IBS Post-Intervention Assessment
Questionnaires. Fresh stools and blood are recollected at this visit to evaluate for possible
change in gut microbiota and cytokines after diet intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |